2024 Abstracts and Poster Presentations
NASP is pleased to present the publication peer-reviewed abstracts that are part of the NASP 2024 Annual Meeting & Expo. NASP extends its heartfelt appreciation to the authors who are participating in the poster display of their work and are on hand to answer attendee questions to further expound on their research and results.
Publication
View all 2024 published abstracts in the Taylor & Francis MEDLINE-indexed journal Current Medical Research & Opinion (CMRO).
Abstracts accepted for presentation at the NASP Annual Meeting & Expo must reflect completed research and are based on the following: novelty of the research, significance of the findings, relevance to specialty pharmacy, and clarity. Submission of previously presented research is permitted.
2024 Poster Winners
With NASP members serving as poster judges, award winners will be announced on Wednesday, October 9 in the following categories:
- Specialty Pharmacy Outcomes & Practice-Based Research: “Exploring the impact of alternative funding programs on medication access and clinical outcomes.” Presenting author: Ana Lopez-Medina, PharmD, RPh, CPS Solutions
- Specialty Pharmacy Products, Services, or Programs: “Net promoter scores demonstrate value of integrated health system specialty pharmacy services.” Presenting author: Sandra Rivera, Shields Health Solutions
- Digital Engagement/Technology in Specialty Pharmacy Services: “Implementation of a flowsheet to track patients with inflammatory bowel disease initiating a biologic with complex dosing regimens.” Presenting author: Kristen Whelchel, PharmD, CSP, Vanderbilt Specialty Pharmacy
- Attendee Choice: “Enhancing specialty pharmacy care through data-driven insights: The value of clinical outcomes dashboards in health system specialty pharmacy.” Presenting author: Diana Miller, Shields Health Solutions
To view abstract posters, please click on the abstract titles below.
OPR1-OR: Assessing value of pharmacist interventions through cost avoidance estimation in an integrated pediatric health-system specialty pharmacy setting
Authors: Jennifer Yen, Children’s Hospital of Orange County; Alice Kim, Children’s Hospital of Orange County; Allison Nguyen, Children’s Hospital of Orange County; Khang Tran, CPS Solutions, LLC; Amanda Cooper, CPS Solutions, LLC; Katie Tu, Children’s Hospital of Orange County
OPR2-OR: Exploring the impact of alternative funding programs on medication access and clinical outcomes
Authors: Ana Lopez-Medina, CPS Solutions, LLC; Trent Towne, CPS Solution; Logan Franke, CPS Solution; Toni Zahorian, CPS Solution; Lori Lane, CPS Solutions, LLC; Amber Skrtic, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Carly Giavatto, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
OPR3-EN: Assessment of the implementation of collaborative pharmacy practice agreements in an integrated health system specialty pharmacy
Authors: Ailsa Watson, Vanderbilt Specialty Pharmacy Student Research Program; Chelsea Renfro, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Bridget Lynch, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Amy Mitchell, Vanderbilt Specialty Pharmacy, Vanderbilt Health
OPR4-EN: Immunization screening prior to initiation of immune modulating medications: a multi-site study
Authors: Amanuel Kehasse, Clearway Health; Kimhouy Tong, Yale New Haven Health; Rena Gosser, UW Medicine; Kate Lewis, Froedtert & the Medical College of Wisconsin; Karen Thomas, University of Illinois Chicago; Stephanie Pilat, University of Rochester Medical Center; Katharine McCarthy, University of Rochester Medical Center
OPR5-OR: Beyond viral load suppression: Role of health system specialty pharmacy in HIV management and opportunistic infections prevention
Authors: Amanuel Kehasse, Clearway Health
OPR6-OR: Values and pitfalls of using Routine Assessment of Patient Index Data 3 (RAPID3) aggregate scores in making clinical interventions in patients with Rheumatoid Arthritis
Authors: Amanuel Kehasse, Clearway Health
OPR7-OR: Leveraging patient reported outcomes data to develop targeted pharmacist interventions in the management of migraine
Authors: Shawn Stanford, Clearway Health; Amanuel Kehasse, Clearway Health
OPR8-EN: Assessment of appropriate anticoagulation in Multiple Myeloma patients- a health system specialty pharmacy retrospective evaluation
Authors: Addie Planas, Baptist Health South Florida; Brittany Alvarez, Baptist Health Specialty Pharmacy; Beatriz Jimenez Cadilla, Baptist Health South Florida; Karina Delgado, Baptist Health Specialty Pharmacy; Jacqualine Igwe, Baptist Health Specialty Pharmacy; Michelle Linh Le, Baptist Health Specialty Pharmacy; Maria Pulido, Baptist Health Specialty Pharmacy; Cristina Vargas, Baptist Health Specialty Pharmacy
OPR9-OR: Analysis of Hepatitis B screening with oral anticancer therapy initiation within a large academic medical center specialty pharmacy
Authors: Anthony Angyal, Cleveland Clinic; Mckay Herpel, Cleveland Clinic; Kristel Geyer, Cleveland Clinic; Shubha Bhat, Cleveland Clinic; Leighton Boquist, Cleveland Clinic
OPR10-EN: Quantifying health-system specialty pharmacists’ interventions for patients utilizing external pharmacies
Authors: Autumn Zuckerman, Vanderbilt Specialty Pharmacy; Amy Mitchell, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Ryan Nix, Vanderbilt Specialty Pharmacy; Kristen Whelchel, Vanderbilt SPecialty Pharmacy
OPR11-EN: Pharmacist-led monitoring for patients initiating PARP inhibitor therapy
Authors: Autumn Zuckerman, Vanderbilt Specialty Pharmacy; Brooke Looney, Vanderbilt Specialty Pharmacy; Stephanie White, Vanderbilt Specialty Pharmacy; Ryan Moore, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Paul Hueseman, AstraZeneca; Kristen Whelchel, Vanderbilt Specialty Pharmacy
OPR12-EN: Risankizumab dose escalation in patients with Crohn’s disease
Authors: Autumn Zuckerman, Vanderbilt Specialty Pharmacy; Patrick Nichols, Vanderbilt Specialty Pharmacy; Jessica Fann, Vanderbilt Specialty Pharmacy; Miranda Kozlicki, Vanderbilt Specialty Pharmacy; Robin Dalal, Vanderbilt University Medical Center
OPR13-OR: Adherence, persistence, and molecular response patterns in patients with CML treated with tyrosine kinase inhibitors in an integrated health system specialty pharmacy
Authors: Bisni Narayanan, Yale New Haven Health; Michele Riccardi, Yale New Haven Health; Christopher Territo, Yale New Haven Health; Thomas Levay, Yale New Haven Health; Andrew Cadorette, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Sam Abdelghany, Yale New Haven Health; Vinay Sawant, Yale New Haven Health; Tina Do, Yale New Haven Health
OPR14-OR: Oral oncology waste in an integrated health system specialty pharmacy
Authors: Bisni Narayanan, Yale New Haven Health; Kimhouy Tong, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
OPR15-EN: A comparison of viral suppression rates of patients receiving Long-Acting Injectable Antiretroviral Therapy (ART) versus oral therapy
Authors: Lillian Gates, Maxor; Justin Lamarca, Maxor; Bonnie Dugie, Maxor
OPR16-OR: Improving ponatinib therapy persistence through nurse-led specialty pharmacy outreach program
Authors: Brittney Lager, AcariaHealth Specialty Pharmacy; Rachel Wiechert, AcariaHealth Specialty Pharmacy; Roy Youn, Takeda Pharmaceuticals; Thomas Pouliot, AcariaHealth Specialty Pharmacy; Robert Allender, AcariaHealth Specialty Pharmacy
OPR17-OR: Big interventions for little patients-A review of pediatric pharmacist interventions within health system specialty pharmacy
Authors: Carly Giavatto, CPS Solutions; Jonathan Weil, CPS Solutions, LLC.; Mindy Roselli, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC
OPR18-EN: Evaluation of a social determinants of health screening and intervention framework within an integrated health system specialty pharmacy care model using a closed-loop referral process
Authors: Carolkim Huynh, Shields Health Solutions; Irfana Lakada, Shields Health Solutions; Andrea Idusuyi, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Martha Stutsky, Shields Health Solutions
OPR19-OR: A health-system specialty pharmacy strategy to optimize medication regimens among patients diagnosed with type 2 diabetes mellitus
Authors: Casey Fitzpatrick, CPS Solutions, LLC; Sali Askar, Mercer College of Pharmacy; Carly Giavatto, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Lauren Bryant, CPS Solutions, LLC; Nicholas McDonald, CPS Solutions, LLC; Elizabeth Carpenter, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
OPR20-EN: Barriers to growth hormone access in pediatric patients at an academic medical center
Authors: Chardé Parrish, Vanderbilt Specialty Pharmacy; Danielle Baird, Vanderbilt Specialty Pharmacy; Terra Redd, Vanderbilt Specialty Pharmacy; Ryan Moore, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Katie Cruchelow, Vanderbilt Specialty Pharmacy
OPR21-EN: Real-world outcomes of patients receiving oral specialty therapy for the treatment of chronic lymphocytic leukemia/small lymphocytic leukemia at an integrated health system in the United States
Authors: Chelsea Renfro, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Houston Wyatt, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Stephanie White, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Hannah Holloway, University of Tennessee Health Science Center College of Pharmacy; Josh DeClercq, Department of Biostatistics, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Karen Carr, BeiGene; Mei Xue, BeiGene USA, Inc.; Swetha Challagulla, BeiGene USA, Inc.; Keri Yang, BeiGene USA, Inc.
OPR22-EN: Development and implementation of collaborative practice agreements in an integrated health system specialty pharmacy: A quantitative analysis
Authors: Chelsea Renfro, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Katie Cruchelow, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Josh DeClercq, Department of Biostatistics, Vanderbilt University Medical Center; Ailsa Watson, Lipscomb University College of Pharmacy; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health
OPR23-EN: Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps
Authors: Chelsea Renfro, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Patrick Nichols, Vanderbilt Specialty Pharmacy, Vanderbilt Healthy; Rachael Baggett, University of Tennessee Health Science Center College of Pharmacy; Jessica Fann, Vanderbilt Specialty Pharmacy; Miranda Kozlicki, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Josh DeClercq, Department of Biostatistics, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health
OPR24-OR: Development of computer-based adherence monitoring of immunosuppressant adherence in kidney transplant patients
Authors: Chris Hayes, Vanderbilt University Medical Center; Keren Rodriguez, Vanderbilt University Medical Center; Rachel Chelewski, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Katie Cruchelow, Vanderbilt Specialty Pharmacy
OPR25-OR: Improving oral oncolytic program: Phase II financial stewardship
Authors: Christine Hong, UT Southwestern; Peggy Bartholomew, UT Southwestern; X. De’Anne Carmichael, UT Southwestern; Shraddha Kansagra, UT Southwestern; Kevin Yutani, UT Southwestern; Arif Shamsul, UT Southwestern; Tayebeh Monabbat, UT Southwestern; Samantha Gates, UT Southwestern; Sonali Niyogi, UT Southwestern; Cristina Hernandez, UT Southwestern; Denise McCauley, UT Southwestern; Waddah Arafat, UT Southwestern; Hetalkumari Patel, UT Southwestern; Donna Bryant, UT Southwestern
OPR26-OR: Using real-world data to better understand biosimilar adoption variation across healthcare provider specialties
Authors: Diane Faraone, PurpleLab; Russell Robbins, PurpleLab; Grace Kane, PurpleLab; Douglas Londono, PurpleLab
OPR27-OR: Impact of clinical pharmacist-led non-oncology infusion management in tertiary academic medical center rheumatology clinic
Authors: Douglas Schneidmuller, Boston Medical Center; Amanuel Kehasse, Clearway Health
OPR28-EN: Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s disease: results from a phase 3 clinical trial
Authors: Subrata Ghosh, APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland; Minhu Chen, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China; Monika Fischer, Indiana University, Indianapolis, Indiana, USA; Marla Dubinsky, Icahn School of Medicine at Mt Sinai, New York, NY, USA; Vipul Jairath, Western University, London, ON, Canada; Alimentiv, London, ON, Canada; Tadakazu Hisamatsu, Kyorin University, Tokyo, Japan; Marc Ferrante, Department of Gastroenterology and Hepatology University Hospitals Leuven, KU Leuven, Belgium; Laurent Peyrin-Biroulet, Nancy University Hospital, Inserm U1256 NGERE, Lorraine University, Lorraine, France; Britta Siegmund, Infectiology and Rheumatology, Charite-Universitatsmedizin, Berlin, Germany; Theresa Gibble, Eli Lilly and Company; Zhantao Lin, Eli Lilly and Company; Marijana Protic, Eli Lilly and Company; Nathan Morris, Eli Lilly and Company; Simon Travis, Kenney Institute, Translational Gastroenterology Unit and Biomedical Research Centre, University of Oxford; Elizabeth Lubelczyk, Eli Lilly and Company
OPR29-RP: Utilizing a transdisciplinary team to enhance specialty pharmacy team’s perception of their readiness to provide PEP patient care
Authors: Catherine Cerulli, University of Rochester Medical Center, Department of Psychiatry, Jennifer Cerulli, Albany College of Pharmacy and Health Sciences; Diane Morse, University of Rochester School of Medicine; Sarahmona Przybyla, University at Buffalo, School of Public Health and Health Professions; John Cullen, University of Rochester Medical Center; Alisha Roberts, Northeast Shared Services; Scott Guisinger, Northeast Shared Services; Janany Jeyakumar; Albany College of Pharmacy
OPR30-OR: An integrated health system specialty pharmacy impacts HIV viral load suppression and maintenance
Authors: Jeremy Spires, Sentara Proprium Pharmacy; James Schwamburger, Sentara Proprium Pharmacy; Patricia Ver Schneider, Sentara Health; Angela Toepp, Sentara Health; Kurayi Mahachi, Sentara Health; Martha Stutsky, Shields Health Solutions; Angelo Jones, Shields Health Solutions
OPR31-OR: Evaluating health literacy and disease activity in patients with rheumatoid arthritis within health-system specialty pharmacy
Authors: Carly Giavatto, CPS Solutions, LLC; Brooke Stephen, Mercer University College of Pharmacy; Anthony DeAngelis, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Amber Skrtic, CPS Solutions, LLC; Jami Schell, Pfizer; Jessica Mourani, CPS Solutions, LLC
OPR32-EN: Cation exchange chromatography: An effective means of removing FXIa from a new 10% intravenous immunoglobulin preparation
Authors: Gil Bu Kang, GC Biopharma; Alan Huber, GC Biopharma USA; Jeungwoon Hong, GC Biopharma; Jihye Lee, GC Biopharma; Min-Jung Kim, GC Biopharma; Eun Bang, GC Biopharma; Seulgi Park, GC Biopharma; Stacy Ness, GC Biopharma USA
OPR33-OR: Optimizing mavacamten clinical and dispensing practices at an integrated specialty pharmacy
Authors: Justin Bivona, Yale New Haven Health; Alec Fouche, Yale New Haven Health; Lauren Voide, Yale New Haven Health; Bisni Narayanan, Yale New Haven Health; Michele Riccardi, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
OPR34-OR: Clinical outcomes in cystic fibrosis patients enrolled in an integrated Health System Specialty Pharmacy (HSSP) Care Model
Authors: Tatyana Cohen, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions; Michaela Wachal, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Kate Smullen, Shields Health Solutions; Martha Stutsky, Shields Health Solutions
OPR35-RP: Effect of specialty pharmacist intervention on recombinant zoster vaccine immunization rates in immunocompromised adults in oncology and HIV clinics
Authors: Katie Richey, Inova Health System; Caitlin Prather, Inova Health System; Mariam Mirkhel, Inova Retail and Specialty Pharmacy
OPR36-OR: Enhancing specialty care: Analysis of interventions by clinical pharmacists within a health-system specialty pharmacy
Authors: Kiersi Harmon, CHRISTUS Health; Alexandra Ritenour, CHRISTUS Health
OPR37-EN: Pediatric hepatitis C patient outcomes in a tertiary academic medical center utilizing an integrated health system specialty pharmacy model
Authors: Alicia Carver, Vanderbilt Specialty Pharmacy; Kristen Whelchel, Vanderbilt Specialty Pharmacy; Cori Edmonds, Vanderbilt Specialty Pharmacy; Ryan Moore, Vanderbilt University Medical Center; Leena Choi, Vanderbilt University Medical Center
OPR38-EN: DAA treatment failure and retreatment strategies following NAT+HCV solid organ transplantation in HCV-negative recipients: A case series
Authors: Alicia Carver, Vanderbilt Specialty Pharmacy; Morgan Lange, The Medical University of South Carolina; Alysa Martin, University of Rochester Medical Center; Claire Ozoral, Ochsner Health; Kristen Whelchel, Vanderbilt Specialty Pharmacy
OPR39-OR: Implementation of the PozQoL in a specialty pharmacy setting: Assessing the impact of pharmacist interventions to improve quality of life in people with HIV
Authors: Advit Shah, CPS Solutions, LLC; Khang Tran, CPS Solutions, LLC; Andrew Wash, CPS Solutions, LLC; Abbas Dewji, CPS Solution; Lily Duong, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Amanda Cooper, CPS Solutions, LLC
OPR40-EN: Evaluating the safety of anti-amyloid monoclonal antibody infusions in alternative sites of care
Authors: Lauren Pica, Soleo Health; Barbara Prosser, Soleo Health; Christine Miller, Soleo Health; Lynn Janssen, Soleo Health
OPR41-OR: Impact of integrated health system specialty pharmacy services and associated patient factors on inflammatory bowel disease outcomes
Authors: Malerie Fiedler, Shields Health Solutions; Bahareh Sameti, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Caleb Chun, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions
OPR42-EN: A preliminary analysis of oral edaravone-treated patients with amyotrophic lateral sclerosis enrolled in a US-based administrative claims database
Authors: Malgorzata Ciepielewska, Mitsubishi Tanabe Pharma America, Inc.; Jeffrey Zhang, Princeton Pharmatech, LLC; Ying Liu, Princeton Pharmatech, LLC; Polina Da Silva, Mitsubishi Tanabe Pharma America, Inc.
OPR43-EN: Healthcare resource utilization of oral edaravone–treated patients with amyotrophic lateral sclerosis enrolled in an administrative claims database
Authors: Malgorzata Ciepielewska, Mitsubishi Tanabe Pharma America, Inc.; Jeffrey Zhang, Princeton Pharmatech, LLC; Ying Liu, Princeton Pharmatech, LLC; Polina Da Silva, Mitsubishi Tanabe Pharma America, Inc.
OPR44-RP: Evaluating the role of social determinants of health and patient demographics on CDK 4/6 inhibitor adherence for breast cancer treatment
Authors: Lena Lebada, AMCP Foundation/Pfizer Oncology Intern with MaxorPlus; Maria Roberts, MaxorPlus
OPR45-OR: Clinical and financial impact of clinical pharmacist interventions in a rural, integrated-health system specialty pharmacy
Authors: Maria Wuerch, Clearway Health; Macy Miller, Clearway Health; Amanuel Kehasse, Clearway Health
OPR46-RP: Evaluation of pharmacist-driven clinical interventions in oncology and hematology patients
Authors: Morgan Petitte, West Virginia University Medicine Specialty Pharmacy; Marisa Barton, West Virginia University Medicine Specialty Pharmacy
OPR47-EN: Impact of pharmacist intervention on herpes zoster vaccination rates in patients with inflammatory disorders prescribed Janus kinase inhibitors (JAKi)
Authors: Marisa Barton, West Virginia University Medicine Specialty Pharmacy; Deborah Pope, West Virginia University Medicine Specialty Pharmacy; Madelyn Harvey, West Virginia University Medicine Specialty Pharmacy; Morgan Petitte, West Virginia University Medicine Specialty Pharmacy
OPR48-OR: Trajectory of asthma control test scores among patients treated within specialty pharmacy
Authors: Alicia Zagel, Fairview Pharmacy Services; Marjorie Wittenbog, Fairview Pharmacy Services; Sandra Ill, Fairview Pharmacy Services; Ann McNamara, Fairview Pharmacy Services
OPR49-OR: Oral oncology inventory management interventions by a specialty pharmacy
Authors: Marjorie Wittenbog, Fairview Pharmacy Services; Erin Kelley, Fairview Pharmacy Services; Tori Grier, Fairview Pharmacy Services; Alicia Zagel, Fairview Pharmacy Services; Ann McNamara, Fairview Pharmacy Services
OPR50-EN: Clinical outcomes of migraine patients receiving calcitonin gene-related peptide antagonists from an integrated health system specialty pharmacy
Authors: Martha Stutsky, Shields Health Solutions; Elizabeth Ilowiecki, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Caleb Chun, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions; Kenny Yu, NYU Langone Health
OPR51-EN: Getting to specialty treatment in dermatologic inflammatory conditions: Treatment requirements and patient journey
Authors: Matthew G Bowles, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Mackenzie Ellis, Lipscomb University College of Pharmacy; Josh DeClercq, Department of Biostatistics, Vanderbilt University Medical Center; Leena Choi, Department of Biostatistics, Vanderbilt University Medical Center; Autumn Zuckerman, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Chelsea Renfro, Vanderbilt Specialty Pharmacy, Vanderbilt Health
OPR52-EN: Clinical and economic burden in people with relapsing-remitting multiple sclerosis in the United States: A matched-cohort study
Authors: Nupur Greene, Sanofi, Cambridge, MA, USA; Ashis K. Das, PHAR, Beverly Hills, CA, USA; Ines Hemim, Sanofi, Cambridge, MA, USA; Eunice Chang, PHAR, Beverly Hills, CA, USA; Marian H. Tarbox, PHAR, Beverly Hills, CA, USA; Keiko Higuchi, Sanofi, Cambridge, MA, USA; Melissa A Geyer, Sanofi
OPR53-EN: Understanding the burden of illness in people with nonrelapsing secondary progressive multiple sclerosis in the United States: A matched-cohort study
Authors: Nupur Greene, Sanofi, Cambridge, MA, USA; Ashis K. Das, PHAR, Beverly Hills, CA, USA; Ines Hemim, Sanofi, Cambridge, MA, USA; Eunice Chang, PHAR, Beverly Hills, CA, USA; Marian H. Tarbox, PHAR, Beverly Hills, CA, USA; Keiko Higuchi, Sanofi, Cambridge, MA, USA; Melissa A Geyer, Sanofi
OPR54-EN: Early achievement of 3- and 6-month treat-to-target goals after 4 weeks of Abrocitinib monotherapy in patients With moderate-to-severe Atopic Dermatitis: A post hoc analysis
Authors: Jonathan Silverberg, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA; Eric Simpson, Oregon Health & Science University, Portland, OR, USA; Marjolein de Bruin-Weller, National Expertise Centre for Atopic Dermatitis, University Medical Centre Utrecht, The Netherlands; Stephan Weidinger, University Hospital Schleswig-Holstein, Kiel, Germany; Peter Nilsson, Pfizer AB, Stockholm, Sweden; Dan Henrohn, Pfizer AB, Stockholm, Sweden; Irina Lazariciu, IQVIA, Kirkland, Quebec, Canada; William Romero, Pfizer Ltd., Surrey, UK; Kris Jaho, Pfizer Inc., New York, NY, USA; Minh Nguyen, Pfizer, Inc.
OPR55-RP: Analysis of real-world adalimumab biosimilar clinical outcomes in the specialty pharmacy setting
Authors: Miranda Fortier, Lumicera Health Services; Amitoj Singh, Lumicera Health Services; Kyle Miller, Lumicera Health Services; Chelsea Hustad, Lumicera Health Services; Kelly Janssens, Lumicera Health Services; Anna Riemer, Lumicera Health Services
OPR56-OR: Impact of an integrated health system specialty pharmacy liaison-managed care model within an uncontrolled diabetes population
Authors: Kristen Lawrence, CHRISTUS Health; Nicholas Bull, CHRISTUS Health; Justin Simon, CHRISTUS Health; Brian Badal, CHRISTUS Health; Shreevidya Periyasamy, Shields Health Solutions; Lillian Piz, Shields Health Solutions; Brandon Vachirasudlekha, Shields Health Solutions
OPR57-RP: The impact of a pharmacist-led patient management program on Inflammatory Disease (ID) for patients of Vivo Health, a health-system owned specialty pharmacy
Authors: Nina Chhabra, Northwell Health- Vivo Health; Agnes Cha, Northwell Health, Vivo Health Pharmacy; Florence Chan, Vivo Health Pharmacy, Northwell Health; Carissa Escober Doran, Vivo Health Pharmacy, Northwell Health; Ashley Galla, Vivo Health Pharmacy, Northwell Health; Almas Hussain, Vivo Health Pharmacy, Northwell Health; Sarah Labib, Vivo Health Pharmacy, Northwell Health
OPR58-EN: Comparative effectiveness of denosumab versus bisphosphonates among treatment-experienced postmenopausal women with osteoporosis in the U.S. Medicare program
Authors: Jeffrey R. Curtis, University of Alabama at Birmingham; Tarun Arora, University of Alabama at Birmingham; Ye Liu, University of Alabama at Birmingham; Vanessa Brunetti, Amgen; Jay Lin, Amgen; Robert Stad, Amgen; Leslie Spangler, Amgen; Michele McDermott, Amgen; Brian Bradbury, Amgen; Min Kim, Amgen; John Roney, Amgen
OPR59-EN: Comparative effectiveness of denosumab versus zoledronic acid among postmenopausal women with osteoporosis in the U.S. Medicare program
Authors: Jeffrey R. Curtis, University of Alabama at Birmingham; Tarun Arora, University of Alabama at Birmingham; Ye Liu, University of Alabama at Birmingham; Vanessa Brunetti, Amgen; Jay Lin, Amgen; Robert Stad, Amgen; Michele McDermott, Amgen; Leslie Spangler, Amgen; Brian Bradbury, Amgen; Min Kim, Amgen; John Roney, Amgen
OPR60-EN: Real-world claims analysis to characterize the burden of tardive dyskinesia in long-term care settings
Authors: Morgan Bron, Neurocrine Biosciences, Inc; Gideon Aweh, STATinMED, LLC; Eric Jen, Neurocrine Biosciences, Inc; Amita Patel, Dayton Psychiatric Associations and Joint Township District Memorial Hospital; Ray Kong, Neurocrine Biosciences, Inc
OPR61-OR: Impact of the Inflation Reduction Act on patient assistant program enrollment for oral hematology and oncology medications managed through a large academic medical health system specialty pharmacy
Authors: Kristel Geyer, Cleveland Clinic; Rebecca Freedman, Cleveland Clinic
OPR62-OR: Migraine diagnoses among United States employees from 2017 to 2022: Real world evidence of calcitonin Gene-Related Peptide inhibitors (CGRPi) and short-term disability utilization
Authors: Richard A Brook, Better Health Worldwide, Inc; Alek A. Drnach, Workpartners; Chester Bernie Good, UPMC; Samuel K. Peasah, UPMC; Eric M. Rosenberg, Workpartners
OPR63-RP: Multiple interventions to reduce delivery costs in a health system pharmacy
Authors: Karen Sorrentino, Yale New Haven Health; Richard Kiley, Yale New Haven Health; Chris Eick, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
OPR64-OR: Impact of a specialty pharmacy clinical program on medical outcomes and costs in patients with cancer
Authors: Lane Beckes, Humana Pharmacy Solutions; Elias Assaf, Humana Pharmacy Solutions; Kara Sperandeo, CenterWell Specialty Pharmacy; Abby Kim, CenterWell Specialty Pharmacy; Kali Sassack, CenterWell Specialty Pharmacy; Megan Winebrenner, CenterWell Specialty Pharmacy; Ryan McDade, CenterWell Specialty Pharmacy
OPR65-OR: Enhancing asthma management: Leveraging ACT screening tools for effective control and patient adherence
Authors: Rumla Rizvi, Yale New Haven Health; Sarah Wright, Yale New Haven Health; Alexandra Mooney, Yale New Haven Health; Bisni Narayanan, Yale New Haven Health; Tina Do, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
OPR66-EN: Adherence for members taking oral oncolytic agents undergoing dose modification strategies
Authors: Timothy Barnett, CVS Health; Cliff Rutter, CVS Health; Shehla Zaidi, CVS Health; Elisea Avalos-Reyes, CVS Health; Kelly McAuliff, CVS Health; Rashmi Grover, CVS Health; Lucia Feczko, CVS Health; Will Cavers, CVS Health; Kjel Johnson, CVS Health
OPR67-OR: The impact of patient characteristics and social drivers of health factors on oral oncolytic adherence
Authors: Sheila Haidar, Stanford Health Care, Priyanka Patneedi, Standford Health Care
OPR68-EN: Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: An interim analysis of the open-label Phase 3b trial, ADmirable
Authors: Andrew Alexis, Weill Cornell Medicine, New York, NY, USA; Ali Moiin, Comprehensive Dermatology Center, Detroit, MI, USA; Jill Waibel, Miami Dermatology and Laser Institute, Miami, FL, USA; Paul Wallace, Wallace Skin Research Center, Los Angeles, CA, USA; David Cohen, Skin Care Physicians of Georgia, Macon, GA, USA; Pearl Kwong, Suncoast Skin Solutions, Inc., Jacksonville, FL, USA; Amber Reck Atwater, Eli Lilly and Company, Indianapolis, IN, USA; Cynthia Harris, Eli Lilly and Company, Indianapolis, IN, USA; Jennifer Proper, Eli Lilly and Company, Indianapolis, IN, USA; Evangeline Pierce, Eli Lilly and Company, Indianapolis, IN, USA; Angela Moore, Baylor University Medical Center, Dallas, TX; Arlington Center for Dermatology, Arlington, TX, USA; Sonya Raikar, Eli Lilly and Company, Indianapolis, IN, USA
OPR69-OR: Impact of pharmacy interns in medication therapy management at an integrated health system specialty pharmacy
Authors: Rebecca Rakiec, Yale New Haven Health; Raye Mutcherson, Yale New Haven Health; Lauren Voide, Yale New Haven Health; Athena Peterson, Yale New Haven Health; Bisni Narayanan, Yale New Haven Health; Mitchell DelVecchio, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health
OPR70-OR: Optimizing patient adherence and engagement through cross-industry collaboration and enhanced patient training and onboarding solutions
Authors: Tim McLeroy, Noble International
OPR71-OR: Real-world evaluation of oncolytic biosimilar adoption on medication adherence and out-of-pocket costs among members of a national payor
Authors: Kelly McAuliff, CVS Health; Cliff Rutter, CVS Health; Timothy Barnett, CVS Health; Elisea Avalos-Reyes, CVS Health; Rashmi Grover, CVS Health; Lucia Feczko, CVS Health; Will Cavers, CVS Health; Dorothea Verbrugge, CVS Health; Kjel Johnson, CVS Health
OPR72-EN: The impact of multiple pharmacy use on medication adherence in individuals with colorectal cancer
Authors: Timothy Barnett, CVS Health; Cliff Rutter, CVS Health; Shehla Zaidi, CVS Health; Elisea Avalos-Reyes, CVS Health; Kelly McAuliff, CVS Health; Rashmi Grover, CVS Health; Lucia Feczko, CVS Health; Will Cavers, CVS Health; Kjel Johnson, CVS Health
DTS73-OR: Integrated financial assistance management in a multi-specialty, multi-tenant pharmacy management system provides indispensable data for improving patient access to specialty medications
Authors: Sophia Clark, House Rx; Catherine Titcomb, House Rx; Janet Ye, House Rx; Jessica Fiant, House Rx
DTS74-RP: Assessing the efficacy of “Mind The Gap” tool and playbook on patient adherence to HIV treatment and prevention Telehealth Services
Authors: Dhvani Derasari, Ravin Consultants; Kirsty Gutierrez, Ravin Consultants; Robert Ferrraro, Ravin Consultants
DTS75-OR: Enhancing specialty pharmacy care through data-driven insights: The value of clinical outcomes dashboards in health system specialty pharmacy
Authors: Carolkim Huynh, Shields Health Solutions; Diana Miller, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Caleb Chun, Shields Health Solutions; Patrick Ryan, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Kate Smullen, Shields Health Solutions; Christopher Barr, Shields Health Solutions
DTS76-EN: Digital patient engagement and improved biosimilar adoption outcomes in specialty pharmacy
Authors: Georgina Masoud, Lumicera Health Services; Miranda Fortier, Lumicera Health Services; Chelsea Hustad, Lumicera Health Services; Eric Huckins, Lumicera Health Services; Collin Wolf, Herspiegel; Albert Wertheimer, Nova Southeastern University
DTS77-EN: Effect of an alternative ordering method at a large mail order specialty pharmacy on patient medication adherence and persistence
Authors: Kelly Mathews, Optum Specialty Pharmacy; Jessica Lynton, Optum Specialty Pharmacy; Melissa Mays, Optum Specialty Pharmacy; Hannah Henderson, Optum Specialty Pharmacy
DTS78-EN: Effect of automated financial assistance engagement at a large mail order specialty pharmacy on patient outcomes
Authors: Kelly Mathews, Optum Specialty Pharmacy; Jessica Lynton, Optum Specialty Pharmacy; Lillianne Do, Optum Specialty Pharmacy; Austin Sadnick, Optum Specialty Pharmacy; Clarisse Purvis, Optum Specialty Pharmacy
DTS79-EN: Assessing the effect of targeted pharmacist interventions in multiple sclerosis patients at high risk for non-adherence from a predictive analytics model at a large mail-order specialty pharmacy
Authors: Kelly Mathews, Optum Specialty Pharmacy; Alexis Smith, Optum Specialty Pharmacy; Jessica Lynton, Optum Specialty Pharmacy; Clarisse Purvis, Optum Specialty Pharmacy
DTS80-EN: Implementation of a flowsheet to track patients with inflammatory bowel disease initiating a biologic with complex dosing regimens
Authors: Jessica Fann, Vanderbilt Specialty Pharmacy; Miranda Kozlicki, Vanderbilt Specialty Pharmacy; , Vanderbilt Specialty Pharmacy; Bridget Lynch, Vanderbilt Specialty Pharmacy, Vanderbilt Health; Kristen Whelchel, Vanderbilt University Medical Center Specialty Pharmacy
DTS81-OR: Implementing targeted adherence outreach for patients with rheumatoid arthritis identified as at risk of nonadherence
Authors: Lily Duong, CPS Solutions, LLC; Josh Bastian, CPS Solutions, LLC; Khang Tran, CPS Solutions, LLC; Abbas Dewji, CPS Solutions, LLC; Pranit Kedarisetty, CPS Solution; Andrew Wash, CPS Solutions, LLC; Courtney Smith, Penn State Health Milton S. Hershey Medical Center
DTS82-OR: Enhancing medication adherence in oncology by leveraging digital channels for medication refills at a specialty pharmacy
Authors: Brittney Lager, AcariaHealth Specialty Pharmacy; Rachel Wiechert, AcariaHealth Specialty Pharmacy; Thomas Pouliot, AcariaHealth Specialty Pharmacy; Robert Allender, AcariaHealth Specialty Pharmacy
DTS83-OR: Harnessing insights: An in-depth look at benchmarking in specialty channels and patient services
Authors: Rob Quinn, Claritas Rx.; Caroline Thompson, Claritas Rx.
DTS84-OR: Optimizing use of electronic patient-reported outcomes (ePROs) to assess and improve disease management
Authors: Merrion Buckley, Pfizer, Inc.; Jeffrey R. Curtis, University of Alabama at Birmingham; Jason Lynn, Pfizer, Inc.; Hesper Chan, Premier, Inc.; Mary E. Bowler, Premier, Inc.; Jeff Vawter, Premier, Inc.; Michele L. Arling, Premier, Inc.; Cate Polacek, Premier, Inc.; Jasmin Thompson, Premier, Inc.; Elizabeth MacLean, Pfizer, Inc.
PSP85-RP: Optimizing HIV pre-exposure prophylaxis services in a primary care settings: Pharmacist-led performance improvement program
Authors: Amanuel Kehasse, Clearway Health
PSP86-OR: Health-system specialty pharmacy role in managing medications for weight loss in patients without evidence of type 2 diabetes
Authors: Andrew Wash, CPS Solutions, LLC; Lauren Bryant, CPS Solutions, LLC; Ana Lopez-Medina, CPS Solutions, LLC; Carly Giavatto, CPS Solutions, LLC; Casey Fitzpatrick, CPS Solutions, LLC; Elizabeth Carpenter, CPS Solutions, LLC; Nicholas McDonald, CPS Solutions, LLC; Brandon Hardin, CPS Solutions, LLC; Jessica Mourani, CPS Solutions, LLC
PSP87-RP: “Senseless and meaningless” – overcoming cultural inertia through innovation and discourse: Developing a documentation tool for clinical interventions and outcomes in specialty pharmacy
Authors: Van Chau, UC Davis Health; Tiffany Phung, UC Davis Health; Jeremiah Duby, UC Davis Health; David Mitchell, UC Davis Health; Erin Tom, UC Davis Health; Catherine Nortell, UC Davis Health; Svetlana Goldman, UC Davis Health; Anh-Thu Truong, UC Davis Health; Mency Zhu, UC Davis Health; Kathie Tran, UC Davis Health; Yi Shi, UC Davis Health; Selina Somani, UC Davis Health
PSP88-OR: The value of a medically integrated pharmacy to maximize cost avoidance and reduce waste of oral oncolytic medications
Authors: Douglas Braun, AON Pharmacy, LLC; Tammy Weinberg, AON Pharmacy
PSP89-RP: Breaking barriers: Patient navigation in specialty pharmacy for chronic hepatitis C treatment access
Authors: Erika Harrington, Cleveland Clinic
PSP90-EN: Contemporary insights into patient and provider perceptions of and barriers to biosimilar use from the Biosim.care web app
Authors: Gary Rice, MedImpact Healthcare Systems, Inc.; Adam Brufsky, University of Pittsburgh Medical Center; Raymond Cross, University of Maryland School of Medicine; Allan Gibofsky, Weill Cornell Medicine; Paula Eichenbrenner, Academy of Managed Care Pharmacy Foundation; Akaimi Davis, Leukemia Patient Advocate; Anna Hyde, Arthritis Foundation; Melodie Narain-Blackwell, Color of Gastrointestinal Illnesses, Inc.; Craig Burton, Biosimilars Council; Jeffrey Carter, PRIME Education; Lindsay Gurska, PRIME Education; Ann Kowalski, PRIME Education; Shelby Sullivan, PRIME Education; Kelly McKinnon, PRIME Education; Marykate Nelson, PRIME Education; Laura Simone, PRIME Education
PSP91-RP: Evaluating the role of a pharmacist in optimizing inflammatory bowel disease treatment
Authors: Hibah Missoum, University of Alabama at Birmingham Hospital; Lauren Holbrook, University of Alabama at Birmingham Hospital
PSP92-OR: One-year outcomes of patient navigation services for patients with bleeding disorders
Authors: Justin Lindhorst, BioMatrix Specialty Pharmacy; Shelby Smoak, BioMatrix Specialty Infusion Pharmacy; Bill Wilbert, BioMatrix Specialty Infusion Pharmacy; Brenda King, BioMatrix Specialty Infusion Pharmacy; Kim Epps, BioMatrix Specialty Infusion Pharmacy
PSP93-OR: Impact of a structured approach to reengage patients lost to follow-up within a health system-based specialty pharmacy
Authors: Kelsey Hennig, Shields Health Solutions; Amelia Persico, Shields Health Solutions; Esther Goldschein, Shields Health Solutions; Martha Stutsky, Shields Health Solutions
PSP94-EN: Development and implementation of an innovative pulmonary arterial hypertension clinical management model
Authors: Kerry Mello-Parker, Shields Health Solutions; Robin Anderton, Shields Health Solutions; Shanna Martin, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Stacy Walton, Shields Health Solutions
PSP95-RP: Analysis of appropriate storage and stability of oral anticancer agents
Authors: Kristel Geyer, Cleveland Clinic; Rebecca Freedman, Cleveland Clinic; Sean Krohn, Cleveland Clinic; Amruth Krishnamurthy, Cleveland Clinic
PSP96-OR: Highlighting the benefits of a personalized onboarding program for clinical pharmacists with diverse work experience
Authors: Lauren Skilton, Shields Health Solutions; Lindsey Bolster, Shields Health Solutions
PSP97-OR: The impact of an ambulatory clinical pharmacist-led obesity management program to improve weight loss goals within an integrated health-system specialty pharmacy
Authors: Mallory Telese, Shields Health Solutions; Kate Smullen, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Carolkim Huynh, Shields Health Solutions; Shreevidya Periyasamy, Shields Health Solutions; Rachel Quinn, Shields Health Solutions; Sharon Zhu, Shields Health Solutions; Kenny Yu, NYU Langone Health
PSP98-OR: Development of a comprehensive workflow for the management of oral anticancer medications in an integrated health system specialty pharmacy
Authors: Michael Zummo, Yale New Haven Health; Vinay Sawant, Yale New Haven Health; Sarah Wright, Yale New Haven Health; Kimhouy Tong, Yale New Haven Health; Mitchell DelVecchio, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Bisni Narayanan, Yale New Haven Health
PSP99-OR: Impact of implementing a pharmacist-led system-wide hepatitis C screening and test-to-treat program
Authors: Michelle Coady, Clearway Health; Amanuel Kehasse, Clearway Health; Richard McCormack, Clearway Health
PSP100-RP: Risk assessment of biohazardous drugs
Authors: Patrick Conley, Merrick
PSP101-OR: Net promoter scores demonstrate value of integrated health system specialty pharmacy services
Authors: Sandra Rivera, Shields Health Solutions; Martha Stutsky, Shields Health Solutions; Channing Garrett, Spartanburg Regional Health System; Sabrina Meadows, Shields Health Solutions; Dylan Collins, Shields Health Solutions
PSP102-OR: Improving employee engagement in a hybrid work setting at an integrated health system specialty pharmacy
Authors: Bisni Narayanan, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Alijah Kosarko, Yale New Haven Health; Diaramalys Rivera, Yale New Haven Health; Brittany Dasher, Yale New Haven Health; Vanessa Batista, Yale New Haven Health; Mitchell DelVecchio, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
PSP103-OR: Implementation of an optimized medication assistance program workflow in a new clinical management platform at an integrated health system specialty pharmacy
Authors: Maline Maldonado, Yale New Haven Health; Wanda Taylor, Yale New Haven Health; Maryann Dulla, Yale New Haven Health; Carolyn Williams, Yale New Haven Health; Danijela Krivokuca, Yale New Haven Health; Franca Pagliaro, Yale New Haven Health; Zach Waggoner, Yale New Haven Health; Lakisha Bobo, Yale New Haven Health; Charles Mattis, Yale New Haven Health; Christopher Graham, Yale New Haven Health; Nathan Simpson, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health
PSP104-OR: Medication assistance program optimization at an integrated health system pharmacy
Authors: Zachery Waggoner, Yale New Haven Health; Wanda Taylor, Yale New Haven Health; Maryann Dulla, Yale New Haven Health; Maline Maldonado, Yale New Haven Health; Danijela Krivokuca, Yale New Haven Health; Franca Pagliaro, Yale New Haven Health; Carolyn Williams, Yale New Haven Health; Terri Sue Rubino, Yale New Haven Health; Vinay Sawant, Yale New Haven Health